INTC
Intel Corporation
INTC offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
MLAB
Mesa Laboratories, Inc.
MLAB has the edge over INTC overall, supported by stronger valuation and lower modeled downside.
INTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Healthy |
INTC's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
MLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Healthy |
MLAB's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
INTC PE Valuation
INTC has no meaningful PE right now: it lost money over the past year.
MLAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $135 | — |
| Current | 118x | $135 | — |
| Cheap | 142x | $163 | +20% |
| Fair | 301x | $346 | +156% |
| Expensive | 570x | $656 | +385% |
Historical ranges are pointers, not guarantees.
MLAB's PE is in its cheap range at 118x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
INTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Broad | |
| Low |
INTC has the edge over MLAB on the outlook, with more favorable revenue expectations.
MLAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLAB's earnings to grow and its profitability to improve, with its revenue holding steady.
INTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | — |
| Q3 2026 | -$2.39 | -24000% |
| Q2 2026 | -$2.09 | +$2.68 |
| Q1 2026 | -$0.60 | +$3.88 |
| Q4 2025 | -$0.06 | +$4.32 |
| Q3 2025 | $0.01 | +$3.72 |
| Q2 2025 | -$4.77 | -2088% |
| Q1 2025 | -$4.48 | -562% |
| Q4 2024 | -$4.38 | -1195% |
INTC has swung to a loss: it lost $2.39 per share over the past year, after a profit the year before.
MLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.01 | +858% |
| Q3 2026 | $1.15 | +$1.46 |
| Q2 2026 | $0.85 | +$0.98 |
| Q1 2026 | $1.21 | +$1.57 |
| Q4 2025 | $0.65 | +$46.97 |
| Q3 2025 | -$0.31 | +$45.31 |
| Q2 2025 | -$0.13 | +$46.35 |
| Q1 2025 | -$0.36 | +$46.84 |
| Q4 2024 | -$46.32 | -25833% |
MLAB has the edge over INTC on earnings quality, reporting a profit while its opponent remains loss making.
INTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.5B | +21% |
| Q2 2026 | $16.1B | +25% |
| Q1 2026 | $13.6B | +7.2% |
| Q4 2025 | $13.7B | -4.1% |
| Q3 2025 | $13.7B | +2.8% |
| Q2 2025 | $12.9B | +0.2% |
| Q1 2025 | $12.7B | -0.4% |
| Q4 2024 | $14.3B | -7.4% |
INTC's revenue is recovering but still below its 2021 peak: $16.5B last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +10 points |
| Q2 2026 | 11% | +36 points |
| Q1 2026 | -23% | -21 points |
| Q4 2025 | 4.2% | +1.4 points |
| Q3 2025 | 5% | +73 points |
| Q2 2025 | -25% | -9.4 points |
| Q1 2025 | -2.4% | +6 points |
| Q4 2024 | 2.9% | -14 points |
INTC has the edge over MLAB on profitability, with a higher operating margin.
MLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | +2.6% |
| Q2 2026 | $60.1M | +1% |
| Q1 2026 | $63.7M | +2.6% |
| Q4 2025 | $65.1M | +3.6% |
| Q3 2025 | $60.7M | +5% |
| Q2 2025 | $59.5M | +2.4% |
| Q1 2025 | $62.1M | +5.5% |
| Q4 2024 | $62.8M | +18% |
MLAB has the edge over INTC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +5.7 points |
| Q2 2026 | 12% | +6.5 points |
| Q1 2026 | 4.3% | +1.9 points |
| Q4 2025 | 12% | +3.1 points |
| Q3 2025 | 7.8% | +1.7 points |
| Q2 2025 | 5.2% | -4.4 points |
| Q1 2025 | 2.4% | +463 points |
| Q4 2024 | 9.2% | +9.3 points |
MLAB's operating margin was 13% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2019.
INTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +774% |
| Q2 2026 | $4.5B | +$6B |
| Q1 2026 | -$2.5B | +$1.8B |
| Q4 2025 | $800M | +$3.5B |
| Q3 2025 | $121M | +$2.5B |
| Q2 2025 | -$1.5B | +$1.9B |
| Q1 2025 | -$4.4B | +$2.8B |
| Q4 2024 | -$2.7B | -$597M |
INTC has the edge over MLAB on cash flow, with more consistent year-over-year improvement.
MLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7M | -48% |
| Q2 2026 | $14.2M | +1504% |
| Q1 2026 | $13.5M | +14% |
| Q4 2025 | $18M | +2.2% |
| Q3 2025 | $7.1M | +105% |
| Q2 2025 | $884K | -91% |
| Q1 2025 | $11.9M | -3.6% |
| Q4 2024 | $17.6M | +69% |
MLAB generated $49M in free cash flow over the past year, up 32% from the year before.
INTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +203M shares |
| 1 year | +17% | +776M shares |
| 3 years | +25% | +1.1B shares |
| 5 years | +30% | +1.2B shares |
| Available history | +19% | +834M shares |
INTC has 5.3B diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $114M |
| Q1 2021 | $2.3B |
MLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3K shares |
| 1 year | +4.1% | +225K shares |
| 3 years | +6.9% | +373K shares |
| 5 years | +7.8% | +416K shares |
| Available history | +32% | +1.4M shares |
MLAB has the edge over INTC on shareholder dilution, with a more favorable share count trend.
INTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q1 2025 | 69.6x | High |
| Q3 2024 | 23.8x | High |
| Q2 2024 | 4.3x | High |
INTC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
MLAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q3 2023 | -1.0x | Net Cash |
MLAB has the edge over INTC on leverage, with a lower net debt burden relative to earnings.
INTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 7.7 | Oversold |
INTC's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
MLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 72.9 | Neutral |
MLAB's weekly RSI is 65 (neutral) and its Stochastic is 73 (neutral).
INTC PE vs Technology Sector
| Metric | INTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
INTC has no meaningful PE right now: it lost money over the past year.
MLAB PE vs Technology Sector
| Metric | MLAB | Sector median | Relative |
|---|---|---|---|
| PE | 118x | 28x | 322% above |
| PE % | 12 | 35 | 23 pts below |
MLAB is trading at 118x earnings, a 322% premium to the Technology sector's median of 28x.
INTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.4 | 31% below |
| 20 week MA | $95.3 | 36% below |
| 50 week MA | $79.3 | 23% below |
| 100 week MA | $52.1 | 18% above |
| 200 week MA | $42.5 | 44% above |
INTC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 44% above its 200-week average.
MLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 4.4% above |
| 20 week MA | $118.6 | 14% above |
| 50 week MA | $102.2 | 32% above |
| 100 week MA | $101.9 | 33% above |
| 200 week MA | $112.8 | 20% above |
MLAB has the edge over INTC on trend strength, trading above more of its moving averages.
INTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.1 | $47.1 | -22% |
| 2021 | $47.1 | $51.3 | +9% |
| 2022 | $51.3 | $26.1 | -49% |
| 2023 | $26.1 | $50.3 | +93% |
| 2024 | $50.3 | $20.3 | -60% |
| 2025 | $20.3 | $36.2 | +78% |
| 2026 YTD | $36.2 | $61.2 | +69% |
INTC has the edge over MLAB on returns for 2026, with the stronger performance.
MLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $247.3 | $284.8 | +15% |
| 2021 | $284.8 | $328.9 | +15% |
| 2022 | $328.9 | $162.8 | -50% |
| 2023 | $162.8 | $104.8 | -36% |
| 2024 | $104.8 | $133.1 | +27% |
| 2025 | $133.1 | $80.5 | -40% |
| 2026 YTD | $80.5 | $135.2 | +68% |
MLAB is up 68% so far in 2026, after finishing lower in three of the previous six years.